ArticleFrontiers in psychiatry2026
Association of oxidative stress, metacognition, and psychopathology in patients with schizophrenia: a case-control study.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metacognitive deficits are common in schizophrenia (SZ) and may worsen symptoms and impair insight. Oxidative stress (OS) abnormalities have also been reported, but findings are inconsistent, and no study has examined their associations with metacognition and psychopathology. Methods: This case-control study included 89 SZ patients and 90 healthy controls (HC). OS markers, including superoxide dismutase (SOD), catalase (CAT), malondialdehyde (MDA), and glutathione peroxidase (GPX) were measured. The patient group and healthy control group underwent metacognition was assessed using the abbreviated Metacognitive Assessment Scale (MAS-A) and patients' symptoms with the Positive and Negative Syndrome Scale (PANSS). Covariates included age, gender, education, BMI, and smoking, illness duration, onset age and medication. Results: Patients showed significantly lower MAS-A total score and subscale scores (all Conclusion: Schizophrenia patients exhibit OS abnormalities and metacognitive impairments. Greater OS severity correlates with worse metacognition and more severe psychopathology, suggesting OS as a key factor linking these domains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.